

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Health Technology Evaluation

Equality impact assessment – Scoping

Pembrolizumab as neoadjuvant (with chemotherapy) and adjuvant (as monotherapy) treatment for resectable non-small-cell lung cancer [ID5094]

The impact on equality has been assessed during this evaluation according to the principles of the NICE Equality scheme.

1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they?
No

2. What is the preliminary view as to what extent these potential equality issues need addressing by the Committee?
NA

3. Has any change to the draft scope been agreed to highlight potential equality issues?
No

4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the stakeholder list been made?
No

Health Technology Evaluation: Scoping
Equality impact assessment for the Health Technology Evaluation of Pembrolizumab as neoadjuvant (with chemotherapy) and adjuvant (as monotherapy) treatment for resectable non-small-cell lung cancer [ID5094]

Approved by Associate Director (name): Ian Watson
Date: 05/01/2024

Health Technology Evaluation: Scoping
Equality impact assessment for the Health Technology Evaluation of Pembrolizumab as
neoadjuvant (with chemotherapy) and adjuvant (as monotherapy) treatment for resectable
non-small-cell lung cancer [ID5094]